JPRN-UMIN000031039
Completed
N/A
Comparison of clinical efficacy between fluticasone propionate/ formoterol (FFC) and fluticasone furoate/ vilanterol (VFC) in patients with asthma - Comparison of clinical efficacy between FFC and VFC
Ikeda Clinic0 sites24 target enrollmentJanuary 29, 2018
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ikeda Clinic
- Enrollment
- 24
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients with evident ACO or COPD comorbidities 2\. Patients with antibiotic\-resistant infections, deep mycosis, or tuberculosis disease 3\. Patients who have been afflicted with a respiratory infection (viral infection) within 8 weeks prior to enrollment 4\. Patients with a smoking history of at least 10 pack years 5\. Patients who have experienced side effects from the use of ICS, LABA or the combined medications 6\. Patients who have used systemic steroids within 4 weeks prior to enrollment 7\. Patients with significant heart, liver, kidney disease or other clinically significant comorbidities 8\. Patients who are pregnant, breastfeeding, or plan to become pregnant during the study period 9\. Other patients who are judged unsuitable for inclusion by the investigators in the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
N/A
Comparison of fluticasone/vilanterol vs fluticasone/salmeterol in stable copd patientsHealth Condition 1: J40-J47- Chronic lower respiratory diseasesCTRI/2022/02/039895SRM college of pharmacy
Completed
N/A
Comparative efficacy of fluticasone furoate/umeclidinium/vilanterol(FF/UMEC/VI)versus budesonide/glycopyrrolate/formoterol fumarate(B/G/F) therapies in COPD patientsCOPDJPRN-UMIN000041089ippon Koukan Hospital50
Active, Not Recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDEUCTR2017-004369-29-ESGlaxoSmithKline, S.A.3,000
Active, Not Recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2017-004369-29-NLGlaxoSmithKline Research & Development Limited3,341
Active, Not Recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2017-004369-29-GBGlaxoSmithKline Research & Development Limited3,000